Seeking Alpha: Receptos Could Meet With A More Positive Reception

Investors do well to be very skeptical of the biotech companies that go public in the late stages of a multi-year bull market. In many case...

Investopedia: Novo Nordisk Getting Its Trial By Fire

The past year or so has shown that Novo Nordisk (NYSE: NVO ) isn't immune from seeing some serious challenges to its business. Betwee...

Investopedia: Does Amgen Deserve To Be Part Of The Biotech Bull Run?

For as much as the sell-side seems to complain about Amgen (Nasdaq: AMGN ), it doesn't seem to have resulted in the company missing ou...

Investopedia: Adasuve Deal Is Very Good For Alexza, But What About Teva?

It was just a week when I wrote that Teva Pharmaceutical (NYSE: TEVA ) seemed undervalued on the basis of its probable free cash flow (FCF)...

Investopedia: Teva Still Too Cheap, But Still Too Uncertain

The story on the generics giant Teva Pharmaceutical (Nasdaq: TEVA ) really hasn't changed all that much over the past year. For invest...